AstraZeneca said its investigational antibody tozorakimab met key goals in two Phase 3 COPD trials, Oberon and Titania, delivering results across a broader patient mix than many biologic-restricted approaches. The company emphasized efficacy for former and current smokers across eosinophil counts and lung-function stages, countering recent disappointment for IL-33 blocker strategies in the broader class.